Co-Diagnostics, Inc. (CODX) stock
CODXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$0.28−0.01 (-3.78%)
Close on Nov 11, 2026Market cap $1.74MP/E –Yield –
Co-Diagnostics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Co-Diagnostics's revenue for the twelve months ending Sep 30, 2026 was $858.89K, up 69.1% year over year. For fiscal 2025 it was $622.49K, down 84.1% from the year before. The highest annual figure on record is $97.89M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $622.49K | -84.1% |
| FY2024 | Dec 31, 2024 | $3.92M | -42.5% |
| FY2023 | Dec 31, 2023 | $6.81M | -80.1% |
| FY2022 | Dec 31, 2022 | $34.22M | -65.0% |
| FY2021 | Dec 31, 2021 | $97.89M | +31.3% |
| FY2020 | Dec 31, 2020 | $74.55M | +34579.9% |
| FY2019 | Dec 31, 2019 | $214.97K | +438.6% |
| FY2018 | Dec 31, 2018 | $39.91K | +420.9% |
| FY2017 | Dec 31, 2017 | $7.66K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $282.88K | +94.6% |
| Q2 FY2026 | Jun 30, 2026 | $166.13K | +2.0% |
| Q1 FY2026 | Mar 31, 2026 | $145.95K | +190.3% |
| Q4 FY2025 | Dec 31, 2025 | $263.92K | +76.7% |
| Q3 FY2025 | Sep 30, 2025 | $145.38K | -77.3% |
| Q2 FY2025 | Jun 30, 2025 | $162.91K | -93.9% |
| Q1 FY2025 | Mar 31, 2025 | $50.28K | -89.3% |
| Q4 FY2024 | Dec 31, 2024 | $149.33K | -95.8% |
| Q3 FY2024 | Sep 30, 2024 | $641.14K | -73.9% |
| Q2 FY2024 | Jun 30, 2024 | $2.66M | +1243.2% |
| Q1 FY2024 | Mar 31, 2024 | $467.85K | -22.3% |
| Q4 FY2023 | Dec 31, 2023 | $3.56M | +153.7% |
| Q3 FY2023 | Sep 30, 2023 | $2.46M | -51.8% |
| Q2 FY2023 | Jun 30, 2023 | $197.81K | -96.1% |
| Q1 FY2023 | Mar 31, 2023 | $601.96K | -97.3% |
| Q4 FY2022 | Dec 31, 2022 | $1.40M | -93.1% |
| Q3 FY2022 | Sep 30, 2022 | $5.09M | -83.1% |
| Q2 FY2022 | Jun 30, 2022 | $5.02M | -81.6% |
| Q1 FY2022 | Mar 31, 2022 | $22.70M | +13.4% |
| Q4 FY2021 | Dec 31, 2021 | $20.40M | -24.8% |
| Q3 FY2021 | Sep 30, 2021 | $30.10M | +38.0% |
| Q2 FY2021 | Jun 30, 2021 | $27.36M | +13.8% |
| Q1 FY2021 | Mar 31, 2021 | $20.02M | +1193.1% |
| Q4 FY2020 | Dec 31, 2020 | $27.15M | +24903.4% |
| Q3 FY2020 | Sep 30, 2020 | $21.82M | +52559.1% |
| Q2 FY2020 | Jun 30, 2020 | $24.04M | +38942.9% |
| Q1 FY2020 | Mar 31, 2020 | $1.55M | +45444.9% |
| Q4 FY2019 | Dec 31, 2019 | $108.57K | +903.1% |
| Q3 FY2019 | Sep 30, 2019 | $41.43K | +327.3% |
| Q2 FY2019 | Jun 30, 2019 | $61.57K | +535.0% |
| Q1 FY2019 | Mar 31, 2019 | $3.40K | -64.9% |
| Q4 FY2018 | Dec 31, 2018 | $10.82K | +316.6% |
| Q3 FY2018 | Sep 30, 2018 | $9.70K | +273.2% |
| Q2 FY2018 | Jun 30, 2018 | $9.70K | +293.2% |
| Q1 FY2018 | Mar 31, 2018 | $9.70K | – |
| Q4 FY2017 | Dec 31, 2017 | $2.60K | – |
| Q3 FY2017 | Sep 30, 2017 | $2.60K | – |
| Q2 FY2017 | Jun 30, 2017 | $2.47K | – |
See a number that looks wrong?